why choose us

First received: March 14, 2023

Clinical Trial: Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

Study Status: Completed

Recruit Status: RECRUITING

Condition: Non-Small Cell Lung Cancer

Study Type: INTERVENTIONAL


Official Title: An Open-Label, Multicenter, Phase 1/1b Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

Brief Summary: This study is a first-in-human (FIH), Phase 1/1b, open-label, multicenter dose escalation and dose expansion study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of JANX008 in adult subjects with advanced or metastatic carcinoma expressing EGFR.

Read more